Innovative Interventional Techniques for Challenging AV-access and PVD
Release time:
2023-03-16
20 March 2023 @ 13:00-14:30 (CET time), 20:00-21:30 (Beijing time)
20 March 2023 @ 13:00-14:30 (CET time), 20:00-21:30 (Beijing time)
Join us for this broadcasted session to hear about the insight from well-known professors on the treatment of challenging AV-access and peripheral vascular disease! Experts will share the innovative interventional techniqueswe with BrosMed Tri-Wedge Scoring PTA balloon to show the advantages of Tri-wedge balloon over conventional PTA balloon.
We’re excited to have Prof. Edwaldo Edner Joviliano as the Moderator, Dr. William Fonseca, Dr. Alessandro Lupi & Dr. Ben Mrad Melek as our expert panel. During the webinar, the experts will discuss innovative interventional techniques, explore the latest advancements and expand the scope of challenging AV-access and peripheral vascular disease treatment.
Don’t miss this ideal opportunity to enhance your specialized knowledge and connect with fellow professionals.
Scan the QR code on the poster or click the Link to register now for closer ties with the experts!
https://live.qing.tv/event/97657530
Stay tuned to join with us and don’t miss out on this exciting event!
Join Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announces Canadian Approval of RevoEdge™ High-Pressure Cutting Balloon
BrosMed Medical today announced Canadian regulatory approval of the RevoEdge™ High-Pressure Cutting Balloon Dilatation Catheter, expanding the company’s presence in North America and marking another milestone in the global commercialization of its specialty coronary portfolio.
2026-09-14
BrosMed Announced CE MDR Approval of VascuGlide™ Microcatheter System
June 15, 2026-BrosMed is pleased to announce that the VascuGlide™ Microcatheter System has received CE MDR certification, marking another significant milestone in the company's commitment to advancing peripheral intervention solutions.
2026-06-18
